Transition Therapeutics Inc. (Transition) is a product-focused biopharmaceutical company developing therapeutics for disease indications with markets. The Company�s wholly-owned subsidiary, Transition Therapeutics Ireland Limited is developing CNS drug candidate ELND005 for the treatment of Alzheimer�s disease and Down syndrome. The Company�s technologies in development include ELND005 for the treatment of Alzheimer�s disease, bipolar disorder and Down syndrome, and TT401/402 for the treatment of diabetes. The Company is engaged in developing disease-modifying small molecule therapeutics that act by preventing the formation of and breaking down amyloid beta peptide aggregates. TT-401 provides glycemic control and other effects, including weight loss.